Brief: Vaxxinity Announces First Parkinson’S Disease Patient Dosed In Part B Of Phase 1 Clinical Trial Of Ub-312
12/01/2022 14:49
Jan 12 (Reuters) - Vaxxinity Inc VAXX.O :
* VAXXINITY ANNOUNCES FIRST PARKINSON’S DISEASE PATIENT
DOSED IN
PART B OF PHASE 1 CLINICAL TRIAL OF UB-312
Source text for Eikon: ID:nGNX5yMrLv
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview